MET and cancer: Recent findings evidenced a synergistic interaction between MET and other RTKs, like EGFR, vascular endothelial growth factor receptor (VEGFR) and insulin-like growth factor-1 receptor (IGF-1R), promoting cancer invasiveness and resistance to chemotherapy [24,25].